15-May-2024

Intravenous Immunoglobulin Market Expected to Grow at 7.0% CAGR, Reaching USD 24.4 Billion by 2032

The Intravenous Immunoglobulin (IVIG) market is projected to experience significant growth, with market size increasing from USD 13.6 billion in 2022 to around USD 24.4 billion by 2032, registering a CAGR of 7.0% between 2023 and 2032. This growth can be attributed to several factors, including the rising prevalence of immunodeficiency diseases and an aging population that is more susceptible to such conditions. The increased adoption of IVIG for treating various neurological, dermatological, and inflammatory conditions also contributes to market expansion.

Recent developments have seen advancements in plasma fractionation and recombinant technologies, enhancing the safety and efficacy of IVIG products. For instance, the approval of new IVIG therapies and innovative subcutaneous immunoglobulin options, which allow for at-home administration, have significantly improved patient convenience and treatment adherence.

However, the market faces challenges such as the high cost of therapy and stringent regulatory requirements, which can hinder wider adoption, especially in developing regions. Additionally, the global plasma shortage and the complex nature of plasma collection and fractionation pose significant supply chain challenges.

Overall, the IVIG market is poised for robust growth, driven by technological advancements and increasing awareness of the benefits of immunoglobulin therapy in managing various immune-related conditions.

Key Takeaways

The Intravenous Immunoglobulin Market size was USD 12.6 billion in 2022.
The market is projected to reach USD 24.4 billion by 2032.
The market will register a CAGR of 7.0% between 2023 and 2032.
North America held a market share of 49.5% in 2022.
Over 500,000 Americans suffer from at least 200 primary immunodeficiency disorders (PIDDs).
IVIG costs USD 73.89 per kilogram.
Treatment using IVIG can cost up to USD 10,000 depending on disease severity.
Long-term replacement therapies using IgG can exceed 30,000 USD annually.
Primary Immunodeficiency held a market share of 31.6% in 2022.
Hospital pharmacies had a revenue share of over 57.3% in 2022.
IVIG therapy consists of 12-16 sessions annually on average.
Grifols S.A. acquired Biotest on April 25, 2022.
70% of 100 people with symptomatic primary, secondary, or autoinflammatory diseases and C1 inhibitor deficiencies were infected by SARS-CoV-2.
69% of those infected were admitted, and 8% died.

Get Sample PDF Report: https://market.us/report/intravenous-immunoglobulin-market/request-sample/

Intravenous Immunoglobulin Market Key Segments

By Type

By Indication

Primary Immunodeficiency
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Guillain-Barre Syndrome (GBS)
Immune Thrombocytopenic Purpura (ITP)
Multifocal Motor Neuropathy (MMN)
Hypogammaglobinemia
Myasthenia Gravis
Specific antibody deficiency
Inflammatory myopathies
Other Indications

By Distribution Channels

Hospital Pharmacy
Retail Pharmacy
Online Pharmacies

Key Regions

North America (The US, Canada, Mexico)
Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)

Buy Directly: https://market.us/purchase-report/?report_id=101568

Key Players Analysis

CSL Behring is a leading player in the intravenous immunoglobulin (IVIG) market, offering a wide range of immunoglobulin therapies. Their portfolio includes products such as Hizentra and Privigen, which are used to treat primary immunodeficiency (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), and other conditions. The company’s strong focus on R&D and recent FDA approvals have bolstered its market position. CSL Behring’s initiatives in plasma collection and advanced purification techniques ensure a steady supply of high-quality IVIG products, driving its growth in the sector.

Shire, now a part of Takeda Pharmaceutical Company, has a significant presence in the IVIG market. Their product, Gammagard, is widely used for treating various immunodeficiency disorders. Takeda’s extensive distribution network and continuous investment in research have enabled the company to maintain a robust market share. The company’s focus on expanding access to IVIG therapies in emerging markets and enhancing production capabilities supports its growth in this competitive landscape.

Grifols is a major global player in the IVIG market, known for its comprehensive range of plasma-derived products. The company’s IVIG offerings, such as Flebogamma and Gamunex, are used to treat PID, CIDP, and other immune disorders. Grifols’ strategic acquisitions, including the purchase of Biotest, have strengthened its market position and expanded its product portfolio. The company’s advanced manufacturing processes and commitment to quality have been pivotal in its market success.

Kedrion is a significant contributor to the IVIG market, focusing on the production of high-quality immunoglobulin products. Their flagship product, KIg10, is used in the treatment of primary immunodeficiency and other immune-related conditions. Kedrion’s strategic partnerships and investments in plasma collection centers have enhanced its supply chain and production capabilities. The company’s dedication to expanding its presence in global markets through innovation and improved access to therapies drives its growth in the IVIG sector.

Octapharma is a prominent player in the IVIG market, offering a diverse range of immunoglobulin products such as Octagam and Panzyga. These products are crucial for treating immune deficiencies, neurological disorders, and other conditions requiring immunoglobulin therapy. Octapharma’s focus on R&D and its state-of-the-art manufacturing facilities have enabled the company to maintain high standards of product quality and efficacy. Their global distribution network ensures widespread availability of their therapies, contributing to their strong market presence.

Intravenous Immunoglobulin Market Key Players:

CSL Behring
Shire (Takeda Pharmaceutical Company Limited)
Grifols S.A.
Kedrion S.p.A
Octapharma
Bio Products Laboratory Ltd.
Biotest AG
China Biologic Products Holdings Inc.
LFB SA
Shanghai RAAS Blood Products Co. Ltd.
Other Key Players

Intravenous Immunoglobulin Market Report Scope >> Market Value (2023): USD 12.6 Billion || Forecast Revenue (2033): USD 24.4 Billion || CAGR (2024-2033): 7% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.

Inquire More about report: https://market.us/report/intravenous-immunoglobulin-market/#inquiry

About Market.US

Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.

Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/